PrismRA® test meets primary endpoints in prospective observational study, predicting inadequate response to anti-TNF therapy in rheumatoid arthritis

In the NETWORK-004 study (391 anti-TNF-naïve and 113 anti-TNF exposed patients), patients with a molecular signature of non-response detected by the test were less likely to have an ACR50 response to anti-TNF at 6 months than those patients lacking the signature (p=0.0001).

Source:

Biospace Inc.